4.6 Article

Effect of β-blocker use on outcomes after discharge in patients who underwent cardiac surgery

Journal

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
Volume 140, Issue 1, Pages 182-U209

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jtcvs.2010.03.015

Keywords

-

Funding

  1. Alberta Heritage Foundation for Medical Research (AHFMR)
  2. University of Alberta/Merck Frosst/Aventis Chair in Patient Health Management
  3. Canadian Institutes of Health Research (CIHR)
  4. Heart and Stroke Foundation of Canada
  5. W. Garfield Weston Foundation
  6. Provincial Wide Services Committee of Alberta Health and Wellness
  7. Merck Frosst Canada
  8. Roche Canada
  9. Eli Lilly Canada
  10. Bristol-Myers Squibb
  11. Philips Medical Systems Canada
  12. Searle Pharmaceuticals
  13. Guidant Corporation
  14. Boston Scientific Ltd
  15. Cordis-a Johnson & Johnson Company

Ask authors/readers for more resources

Objective: beta-Blockers improve outcomes in patients with heart failure or a history of myocardial infarction, but it remains uncertain whether they are beneficial after the perioperative period in cardiac surgery patients without these conditions. This study was designed to examine whether discharge use of beta-blockers was associated with outcomes after hospitalization in patients who had undergone nontransplant cardiac surgery. Methods: We analyzed outcomes in a prospective cohort of 3102 patients discharged alive after cardiac surgery (2547 of whom had undergone coronary artery bypass grafting surgery) between September 2002 and August 2005. Results: beta-Blockers were prescribed for 2580 (83%) patients at hospital discharge. Over a mean follow-up of 75 months (standard deviation, 20 months), 10% (259/2580) of patients discharged with beta-blockers and 19% (97/522) not prescribed beta-blockers at the time of hospital discharge died (hazard ratio of 0.65 [95% confidence interval, 0.49-0.87] after adjustment for covariates). One-year mortality was also lower in those discharged with beta-blockers: 2.2% (57/2580) in beta-blocker users versus 7.2% (38/522) in nonusers (adjusted odds ratio, 0.54 [95% confidence interval, 0.30-0.97]). The association between beta-blocker use and lower mortality was consistent across all examined subgroups, including patients without prior myocardial infarction or without heart failure (all P < .01). Conclusions: Patients discharged with beta-blockers after cardiac surgery exhibit a substantially lower mortality rate during long-term follow-up, even among those without a history of myocardial infarction or heart failure. (J Thorac Cardiovasc Surg 2010; 140: 182-7)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available